PECATI
Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents
- NCT04710628 ↗
- Completed
- MedSIR
- Standard
We haven't built an HCP commentary report on PECATI (lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated from all 14 indexed sources (Sep 2021 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether PD-L1 predicts benefit from lenvatinib and pembrolizumab
- Whether randomized evidence can clarify the regimen’s benefit relative to other options
- How to manage treatment-related toxicity, including immune-related effects
Also discussed: lenvatinib dose intensity.
Indexed commentary on PECATI so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 12 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic Carcinoma PaTIents. PECATI.
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Metastatic Thymic Carcinoma; Thymoma Type B3
- Interventions
- Pembrolizumab; Lenvatinib 10 mg
- Arms
- PEMBROLIZUMAB + LENVATINIB · Experimental
- Enrollment
- 43
- Primary outcomes
- Progression-free survival (PFS)
- Sponsor
- MedSIR with Merck Sharp & Dohme LLC
- Start
- Sep 21, 2021
- Primary completion
- Jul 1, 2024
- Results posted
- No
- Registry record
- NCT04710628 · updated Feb 19, 2026
Publications
linked from the registry- Remon J, Bironzo P, Girard N, Bigay-Game L, Juan-Vidal O, de Castro J, Reguart N, Greillier L, Cousin S, Dansin E, Majem M, Bernabe R, Mosquera Martinez J, Diaz M, Meya A, Alcala-Lopez D, Garcia-Sanz A, Righi L, Novello S, Besse B. Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial. Lancet Oncol. 2025 Sep;26(9):1215-1226. doi: 10.1016/S1470-2045(25)00300-6. PubMed 40907517